Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04921904 · ClinicalTrials.gov registry record · Phase 1

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

A Phase 1 study of Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Esophageal Adenocarcinoma, sponsored by Baylor Research Institute.

Active
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT04921904 is a Phase 1 study of Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Esophageal Adenocarcinoma that is active but no longer recruiting, run by Baylor Research Institute. The registered enrollment target is 8 participants, below the 41-participant average among 8 other Metastatic Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04921904, a Phase 1 study of Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Esophageal Adenocarcinoma, is active but no longer recruiting, sponsored by Baylor Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.

Conditions Studied

Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Esophageal Adenocarcinoma

Interventions

  • DRUG Abemaciclib
  • DRUG Ramucirumab

Study Locations (1)

Texas

  • Baylor University Medical Center, Charles A Sammons Cancer Center - Dallas

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2021-06-11
Est. Completion 2026-06
Phase Phase 1

Sponsor

Baylor Research Institute

180 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04921904

The ClinicalTrials.gov registry entry for NCT04921904 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 8 other Metastatic Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (80% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.

NCT04921904 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04921904 about?

NCT04921904 is a clinical study titled "Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca". CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.

What is the current status of trial NCT04921904?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-06-11. Estimated completion is 2026-06.

What conditions does trial NCT04921904 study?

This clinical trial studies the following conditions: Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma.

What interventions are being tested in trial NCT04921904?

The interventions under investigation include: Abemaciclib (DRUG), Ramucirumab (DRUG).

Who is sponsoring clinical trial NCT04921904?

This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04921904 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Gastroesophageal Junction Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Gastroesophageal Junction Adenocarcinoma

All registered trials for this condition

Metastatic Esophageal Adenocarcinoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.